Press Releases

20/05/2021 OSE Immunotherapeutics and Boehringer Ingelheim Present Positive Phase 1 Results with BI 765063

18/05/2021 OSE Immunotherapeutics Announces €10.7 Million in Additional Public Funding, via Bpifrance

26/04/2021 OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement for FR 104

06/04/2021 OSE Immunotherapeutics Announces First Peer-Reviewed Publication in Science Advances on OSE-230

01/04/2021 OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of CoVepiT

26/03/2021 OSE Immunotherapeutics Reports 2020 Financial Results

15/03/2021 OSE Immunotherapeutics and ARCAGY - GINECO Announce Initiation of a Randomized Phase 2 Clinical Trial

11/03/2021 OSE Immunotherapeutics to Present New Data at AACR 2021

23/02/2021 OSE Immunotherapeutics Presentation at H.C. Wainwright Global Life Sciences Conference

17/02/2021 OSE Immunotherapeutics Announces Granting of First European Patent Protecting OSE-127

15/02/2021 OSE Immunotherapeutics Enters a Loan Agreement of up to €25 Million with the European Investment Bank

28/01/2021 OSE Immunotherapeutics Expands its Collaboration with MAbSilico

26/01/2021 INCREASE IN RESOURCES DEVOTED TO THE LIQUIDITY CONTRACT OSE IMMUNOTHERAPEUTICS

25/01/2021 OSE Immunotherapeutics Receives €1.3 Million Milestone Payment from Bpifrance for OSE-127/S95011

05/01/2021 OSE Immunotherapeutics Presentation at H.C. Wainwright BIOCONNECT 2021

21/12/2020 OSE Immunotherapeutics Announces Enrolment of First Patient with Ulcerative Colitis in Phase 2

18/12/2020 OSE Immunotherapeutics Receives €5.2 M in Public Funding

03/12/2020 OSE Immunotherapeutics and Nantes University Hospital Announce Initiation of a Phase 1/2 of FR104

1 2 3 4 5 6 7 8 9 10 11 12 13 14